Case Study: Personalized Oral Low-dose Naltrexone Titration for Pain Management

Author(s):  Rodriguez Franklin, Carvalho Maria, Banov Fabiana

Issue:  Nov/Dec 2023 - Volume 27, Number 6
View All Articles in Issue

Abstract:  Naltrexone is a competitive opioid receptor antagonist indicated to treat opioid and alcohol dependence. In the U.S., naltrexone is commercially available as 50-mg tablets, and the adult dosage strength typically ranges between 50 mg once daily and 100 mg once daily. However, there is evidence to suggest that naltrexone prescribed in low doses, about 1/10th of the daily standard dosage, may be effective in managing a myriad of chronic conditions, including pain refractory to conventional pharmacological treatments. The U.S. Food and Drug Administration recently granted an orphan drug designation for low-dose naltrexone for the treatment of complex regional pain syndrome. This article provides a case study of a patient who was treated with a low dose of naltrexone for pain associated with the diagnosis of idiopathic hypereosinophilic syndrome.

Related Keywords: low-dose naltrexone, formulation, pain management, complex regional pain syndrome, case report, idiopathic hypereosinophilic syndrome, mepolizumab, analgesia, inflammation, analgesic agent, anti-inflammatory agent, Neuropathic Pain Symptom Inventory, NPSI, dose titration, dose increases, patient assessment, pain intensity

Related Categories: FORMULATIONS, PAIN MANAGEMENT, CASE REPORTS, PATIENT ASSESSMENT

Purchase this article for download in electronic PDF format from IJPC at for $75 at:
https://ijpc.com/Abstracts/Abstract.cfm?ABS=5270

Search the entire IJPC archive by keyword, topic, or issue at:
https://ijpc.com/Products